Effect of sugar cane policosanol on lipid profile in primary hypercholesterolemia

Phytotherapy Research

Volumn 22, Issue 3, 2008, Pages 318-322

  Francini Pesenti, F ^a   Beltramolli, D ^a   Dall'Acqua, S ^b   Brocadello, F ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Clinical trial; Hypercholesterolemia; Sugar cane policosanol

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CALORIC INTAKE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GAS CHROMATOGRAPHY; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MALE; RANDOMIZED CONTROLLED TRIAL; SUGARCANE; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; BODY MASS INDEX; CHOLESTEROL; DOUBLE-BLIND METHOD; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LIPIDS; MALE; MIDDLE AGED; PHYTOTHERAPY; PLANT EXTRACTS; SACCHARUM; TRIGLYCERIDES;

SACCHARUM;

EID: 40849094376     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.2315     Document Type: Article

References (37)

1. Aleman CL, Mas R, Hernandez et al. 1994. A 12-month study of policosanol oral toxicity in Sprague Dawley rats. Toxicol Lett 70: 77-87.
2. Aleman CL, Puig MN, Elias EC et al. 1995. Carcinogenicity of policosanol in mice: an 18-month study. Food Chem Toxicol 33: 573-578.
3. Aleman C, Rodeiro I, Noa M et al. 2001. One-year dog toxicity study of D-002, a mixture of aliphatic alcohols. J Appl Toxicol 21: 179-184.
4. Arruzazabala ML, Noa M, Menendez R et al. 2000. Protective effect of policosanol on atherosclerotic lesions in rabbits with exogenous hypercholesterolemia. Braz J Med Biol Res 33: 835-840.
5. Berthold HK, Unverdorben S, Degenhardt R, Bulitta M, Gouni-Berthold I. 2006. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia. JAMA 295: 2262-2269.
6. Canetti M, Moreira M, Mas R et al. 1995. A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia. Int J Clin Pharmacol Res 15: 159-165.
7. Castano G, Fernandez L, Mas R et al. 2002. Comparison of the efficacy, safety and tolerability of original policosanol versus other mixtures of higher aliphatic primary alcohols in patients with type II hypercholesterolemia. Int J Clin Pharmacol Res 22: 55-66.
8. Castano G, Mas R, Arruzazabala ML et al. 1999. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients. Int J Clin Pharmacol Res 19: 105-116.
9. Castano G, Mas R, Fernandez L et al. 2003. Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolemia. Drugs Aging 20: 153-163.
10. Crespo N, Illnait J, Mas R, Fernandez L, Fernandez J, Castano G. 1999. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus. Int J Clin Pharmacol Res 19: 117-127.
11. Dulin MF, Hatcher LF, Sasser HC, Barringer TA. 2006. Policosanol is ineffective in the treatment of hypercholesterolemia: a randomized controlled trial. Am J Clin Nutr 84: 1543-1548.
12. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) (Adult Treatment Panel III). 2001. JAMA 285: 2486-2497.
13. Fernandez JC, Mas R, Castano G et al. 2001. Comparison of the efficacy, safety and tolerability of policosanol versus fluvastatin in elderly hypercholesterolaemic women. Clin Drug Investig 21: 103-113.
14. Friedewald WT, Levy RI, Fredrickson DS. 1972. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502.
15. Gamez R, Aleman CL, Mas R et al. 2001. A 6-month study on the toxicity of high doses of policosanol orally administered to Sprague-Dawley rats. J Med Food 4: 57-65.
16. Gonzalez VL, Hernandez J. 1999. Validation of a gas chromatographic method for determining fatty alcohol that compose policosanol in five-milligram film-coated tablets. AOAC Int 82: 834-839.
17. Gouni-Berthold I, Berthold HK. 2002. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 143: 356-365.
18. Greyling A, De Witt C, Oosthuizen W, Jerling JC. 2006. Effects of a policosanol supplement on serum lipid concentrations in hypercholesterolaemic and heterozygous familial hypercholesterolaemic subjects. Br J Nutr 95: 968-975.
19. Hargrove JL, Greenspan P, Hartle DK. 2004. Nutritional significance and metabolism of very long chain fatty alcohols and acids from dietary waxes. Exp Biol Med 229: 215-226.
20. Howard BV, Hannah JS, Heiser CC, Jablonski KA. 1995. Effects of sex and ethnicity on responses to a low-fat diet: a study of African Americans and whites. Am J Clin Nutr 62: 488S-492S.
21. Janikula M. 2002. Policosanol: a new treatment for cardiovascular disease? Altern Med Rev 7: 203-217.
22. Kassis AN, Jones PJ. 2006. Lack of cholesterol-lowering efficacy of Cuban sugar cane policosanols in hypercholesterolemic persons. Am J Clin Nutr 84: 1003-1008.
23. Lin Y, Rudrum M, van der Wielen RP et al. 2004. Wheat germ policosanol failed to lower plasma cholesterol in subjects with normal to mildly elevated cholesterol concentrations. Metabolism 53: 1309-1314.
24. Mariangeli CPF, Kassis AK, Jain D, Ebine N, Cunnane SC, Jones PJH. 2007. Comparison of composition and absorption of sugarcane policosanols. Br J Nutr 97: 381-388.
25. Menendez R, Amor AM, Rodeiro I et al. 2001. Policosanol modulates HMG-CoA reductase activity in cultured fibroblasts. Arch Med Res 32: 8-12.
26. Menendez R, Arruzazabala L, Mas R. 1997. Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolaemia induced by a wheat starch-casein diet. Br J Nutr 77: 923-932.
27. Menendez R, Fernandez SI, Del Rio A et al. 1994. Policosanol inhibits cholesterol biosynthesis and enhances low density lipoprotein processing in cultured human fibroblasts. Biol Res 27: 199-203.
28. Murphy KJ, Saint DA, Howe PR. 2004. Lack of effect of sugar cane and sunflower seed policosanols on plasma cholesterol in rabbits. Asia Pac J Clin Nutr 13: S69.
29. Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J. 2005. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the Ezetimibe Add-on to Statin for Effectiveness (EASE) trial. Mayo Clin Proc 80: 587-595.
30. Pons P, Rodriguez M, Robaina C et al. 1994. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment. Int J Clin Pharmacol Res 14: 27-33.
31. Rodriguez MD, Garcia H. 1994. Teratogenic and reproductive studies of policosanol in the rat and rabbit. Teratog Carcinog Mutagen 14: 107-113.
32. Rodriguez MD, Garcia H. 1998. Evaluation of peri- and post-natal toxicity of policosanol in rats. Teratog Carcinog Mutagen 18: 1-7.
33. Rodriguez-Echenique C, Mesa R, Mas R et al. 1994. Effects of policosanol chronically administered in male monkeys (Macaca arctoides). Food Chem Toxicol 32: 565-575.
34. Singh DK, Li L, Porter TD. 2006. Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase. J Pharmacol Exp Ther 318: 1020-1026.
35. Tan CE, Loh LM, Tai ES. 2003. Do Singapore patients require lower doses of statins? the SGH Lipid Clinic experience. Singapore Med J 44: 635-638.
36. Torres O, Agramonte AJ, Illnait J, Mas Ferreiro R, Fernandez L, Fernandez JC. 1995. Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care 18: 393-397.
37. Wang YW, Jones PJ, Pischel I, Fairow C. 2003. Effects of policosanols and phytosterols on lipid levels and cholesterol biosynthesis in hamsters. Lipids 38: 165-170.